Scienmag

APRIL 22, 2021

Researchers have found that a natural molecule can effectively block the binding of a subset of human antibodies to SARS-CoV-2. The discovery may help explain why some COVID-19 patients can become severely ill despite having high levels of antibodies against the virus.

Antibody 59

Antibody Scientist Research Medicine 59

Scienmag

OCTOBER 26, 2021

A study conducted by a consortium of Brazilian researchers has demonstrated that a hyperimmune serum consisting of purified antibody fragments produced in horses may be an efficient approach to combat covid-19. The neutralizing activity of the sera developed by the scientists has been proved to be […].

Antibody 76

Antibody Scientist Development Research 76

Scienmag

OCTOBER 21, 2021

WHAT: A booster dose of the mRNA-1273 COVID-19 vaccine given to rhesus macaques about six months after their primary vaccine series significantly increased levels of neutralizing antibodies against all known SARS-CoV-2 variants of concern, according to a new study from National Institutes of Health scientists and colleagues.

Antibody 70

Antibody Vaccination Vaccine Scientist 70

Scienmag

FEBRUARY 25, 2021

Research from the California Institute of Technology shows exactly how antibodies stick to and block the Zika virus, which will inform vaccine development Credit: Image courtesy of Shannon Esswein.

Antibody 52

Antibody Scientist Vaccination Vaccine 52

Scienmag

JUNE 29, 2021

Six antibody features help protect pregnant women against placental malaria infections, and could be used to identify women at risk of the disease and related complications Six antibody characteristics could help scientists identify which pregnant women are at risk of placental malaria infections, finds a study published today in eLife.

Antibody 65

Antibody Scientist Allergies Medicine 65

Scienmag

OCTOBER 22, 2020

The testing criteria had yet to be expanded to include individuals with Smith’s symptoms and so he did what many scientists with […]. Stephen Smith of Seattle Children’s Research Institute came down with muscle aches, gastrointestinal distress and a sudden loss of smell in late February, he suspected he had COVID-19.

Scientist 52

Scientist Antibody Development Research 52

pharmaphorum

MAY 3, 2022

A scientist working in Switzerland has become the fifth person to be convicted of attempting to steal trade secrets from pharmaceutical group GlaxoSmithKline in a case that stretched back several years. ” The post Fifth scientist convicted in GSK trade secrets case appeared first on.

Scientist 69

Scientist Branding Production Antibody 69

Scienmag

APRIL 22, 2021

SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity Researchers have identified another potential target for neutralizing antibodies on the SARS-CoV-2 Spike protein that is masked by metabolites in the blood.

Antibody 46

Antibody Protein Scientist Research 46

The Pharma Data

JUNE 30, 2021

For their remarkable scientific contributions, doctoral student Julia Klaus, Zurich University VetSuisse Faculty, and Dr Yasmin Parr from the MRC-University of Glasgow, Centre for Virus Research, have received the 2021 ABCD Young Scientist Award. To foster young talent development in the feline health research community.

Scientist 52

Scientist Immune Response Antibody Development 52

The Pharma Data

FEBRUARY 12, 2022

The discovery, published in Science Translational Medicine, could inform the design of broad-acting vaccines and antibody therapies capable of stopping future coronavirus pandemics. In the new work, they mapped at atomic scale the site, or “epitope,” to which the antibody binds on the SARS-Cov-2 spike protein.

Scientist 52

Scientist Antibody Protein Vaccination 52

Scienmag

NOVEMBER 2, 2020

2, 2020 – University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19. Credit: UPMC PITTSBURGH, Nov.

Antibody 40

Antibody Scientist Medicine Allergies 40

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. What advantages do they offer over antibodies?   To what do you attribute your success?

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Scienmag

JUNE 1, 2021

Army scientists working as part of an international consortium have developed and tested an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus (CCHFV), which is carried by ticks and kills up to 60 percent of those infected. Their results are published online today in the journal Cell.

Scientist 57

Scientist Development Antibody Allergies 57

Scienmag

NOVEMBER 4, 2020

Credit: Rayne Zaayman-Gallant/EMBL The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2. To enable the virus to hook onto the cell surface, the spike protein binds ACE2 using three finger-like protrusions, called the receptor binding domains (RBDs).

Scientist 65

Scientist Antibody Protein Medicine 65

Scienmag

DECEMBER 23, 2021

Credit: Julianna Han, Ward Lab at Scripps Research LA JOLLA, CA—Scientists at Scripps Research, University of Chicago and Icahn School of Medicine at Mount Sinai have identified a new Achilles’ heel of influenza virus, making progress in the quest for a universal flu vaccine.

Vaccination 96

Vaccination Vaccine Research Antibody 96

Scienmag

AUGUST 17, 2020

— University of Wisconsin-Madison scientists have discovered that a majority of back-pain patients they tested who were taking opioid painkillers produced anti-opioid antibodies. These antibodies may contribute to some of the negative side effects of long-term opioid use. MADISON, Wis.

Antibody 50

Antibody Scientist Vaccination Vaccine 50

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

The Pharma Data

DECEMBER 7, 2020

7, 2020 — Scientists say they may be getting closer to creating a universal flu vaccine. The vaccine produces antibodies that target the part of the surface protein of the influenza virus known to neutralize different influenza strains, the researchers said. 7 in the journal Nature Medicine. MONDAY, Dec. © 2020 HealthDay.

Scientist 52

Scientist Vaccination Vaccine Immune Response 52

Scienmag

DECEMBER 16, 2020

Scientists at the Ragon Institute of MGH, MIT and Harvard find that neutralizing antibody potency predicts severe or fatal COVID-19. Of particular interest are neutralizing antibodies, which can block the virus from […]. Of particular interest are neutralizing antibodies, which can block the virus from […].

Antibody 40

Antibody Immune Response Scientist Vaccination 40

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccination 75

Vaccination Vaccine Immune Response Containment 75

Scienmag

SEPTEMBER 18, 2020

Antibody-like proteins that capture and neutralize SARS-CoV-2 Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus – 4 of which also exhibited neutralizing activity – within 4 days, according to a new study.

Protein 53

Protein Antibody In-Vitro Scientist 53

Scienmag

DECEMBER 23, 2021

A team led by scientists at Weill Cornell Medicine, Scripps Research and the University of Chicago has identified an important site of vulnerability on influenza viruses—a site that future influenza vaccines and antibody therapies should be able to target to prevent or treat infections by a broad set of influenza strains.

Vaccination 67

Vaccination Vaccine Scientist Antibody 67

pharmaphorum

FEBRUARY 19, 2021

The two Canadian researchers – Danuta Skowronski and Gaston De Serres – make the suggestion in a letter to the New England Journal of Medicine, in which they say the shot has more than 90% efficacy after one dose. The post Scientists make case for one dose of Pfizer’s COVID jab to stretch supplies appeared first on.

Scientist 73

Scientist Vaccination Vaccine Antibody 73

Scienmag

JANUARY 25, 2021

OHSU study has important implications for vaccines, diagnosis of COVID-19 A new study demonstrates that antibodies generated by the novel coronavirus react to other strains of coronavirus and vice versa, according to research published today by scientists from Oregon Health & Science University.

Antibody 40

Antibody Scientist Vaccination Vaccine 40

Scienmag

MARCH 23, 2021

SINGAPORE, 23 March 2021 – Scientists from Duke-NUS Medical School, the National Centre for Infectious Diseases (NCID) and the Agency for Science, Technology and Research (A*STAR) Infectious Diseases Labs found that antibodies against SARS-CoV-2 wane at different rates, lasting for mere days in some individuals, while remaining present in others (..)

Antibody 41

Antibody Scientist Research Medicine 41

Scienmag

OCTOBER 23, 2020

Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch

Recombinant Antibody 53

Recombinant Antibody Protein Antibody In-Vivo 53

Drug Discovery World

APRIL 11, 2024

By understanding what triggers the adaptive immune response in “elite responders” we have identified new targets and therapeutic antibodies. Anyone involved in developing medicines from an early stage, knows that the road from idea to patients is full of unexpected trials and tribulations.

Research 59

Research Immune Response Antibody Medicine 59

Scienmag

FEBRUARY 4, 2022

PHILADELPHIA — (Feb. 4, 2022) — Nearly four decades after its discovery, HIV has killed 36.3 million people, with no vaccine in sight.

Vaccination 81

Vaccination Vaccine Development Research 81

Scienmag

APRIL 9, 2021

Using a novel toolkit of approaches, the scientists uncovered the […].

Antibody 93

Antibody Protein Scientist Research 93

Drug Discovery World

MAY 30, 2024

It is these lymph nodes which help to make proteins called antibodies that protect from infection. KP: Our research is conducted by a multidisciplinary team of clinicians, scientists, and research nurses, and is a collaboration of different research sites with specialist facilities.

Vaccination 59

Vaccination Vaccine Scientist Clinical Trials 59

Drug Discovery World

DECEMBER 22, 2023

In other news, the FDA approved a promising antibody-drug conjugate for bladder cancer and trial results demonstrated that psilocybin could reduce depression symptoms in cancer patients. In the study, trial participants treated with psilocybin not only experienced a lessening of depressive symptoms but also spoke highly of the therapy.

Drugs 52

Drugs Antibody FDA Approval Clinical Trials 52

The Pharma Data

JANUARY 12, 2021

LONDON, UK / ACCESSWIRE / January 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company (“GlobalCo”).

Antibody 40

Antibody Development Licensing Licensing 40

Drug Discovery World

JANUARY 19, 2024

The top stories: Antibody cocktail effective against emerging Covid-19 variants Biotech company ExeVir Bio has revealed new data demonstrating that its antibodies are effective in neutralising currently circulating Covid-19 Omicron variants.

Drugs 52

Drugs Vaccination Vaccine Genetics 52

Scienmag

MAY 12, 2021

Scripps Research scientists propose an innovative vaccine approach to protect against a troublesome family of viruses that present a major global health risk LA JOLLA, CA–Scientists at Scripps Research have unveiled a new Ebola virus vaccine design, which they say has several advantages over standard vaccine approaches for Ebola and related viruses (..)

Vaccination 47

Vaccination Vaccine Antibody Scientist 47

The Pharma Data

JANUARY 12, 2021

million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. Under the new agreement, the government will purchase all finished doses of the casirivimab and imdevimab antibody cocktail delivered by June 30, 2021 , up to 1.25 TARRYTOWN, N.Y. , 12, 2021 /PRNewswire/ — . million doses.

Antibody 52

Antibody Production Manufacturing Clinical Trials 52

The Pharma Data

MARCH 22, 2021

Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by four days. The combination of casirivimab and imdevimab is the only monoclonal antibody treatment to retain potency against key emerging variants, based on the recently updated EUA guidance from the U.S.

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 18, 2020

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. We are excited about the potential for one medicine to serve both as a treatment for those infected as well as protection for people exposed to the virus. and around the world.

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52